Associate Scientist Takeda Pharmaceutical Company Limited Fujisawa, Kanagawa, Japan
LC-MS-based proteomics has had a significant impact on biomarker discovery. However, the complexity of the instruments, data acquisition methods, and analysis methods makes it very difficult to gain an overview of the entire process. When it comes to drug development, the quantification accuracy is very important to evaluate drug dosage and efficacy. In this presentation, the presenter will give an overview of information around LC-MS-based proteomics and will also discuss the current findings on quantitation.
Learning Objectives:
Participants will be able to understand the updated high plex LC-MS-based proteomics platform and its advantages over the conventional platform.
Participants will be able to understand the updated software for high plex proteomics data analysis and its features.
Participants will be able to provide a case study of data integration for biomarker discovery.
